WallStSmart

BeiGene, Ltd. (ONC)vsOSR Holdings Inc (OSRH)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

BeiGene, Ltd. generates -5903025% more annual revenue ($5.34B vs $-90,515). ONC leads profitability with a 5.4% profit margin vs 0.0%. ONC earns a higher WallStSmart Score of 42/100 (D).

ONC

Hold

42

out of 100

Grade: D

Growth: 8.0Profit: 5.0Value: 3.0Quality: 6.5
Piotroski: 5/9Altman Z: 0.26

OSRH

Avoid

23

out of 100

Grade: F

Growth: 3.7Profit: 2.5Value: 5.0Quality: 5.0
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

ONCSignificantly Overvalued (-1983.5%)

Margin of Safety

-1983.5%

Fair Value

$16.86

Current Price

$283.45

$266.59 premium

UndervaluedFair: $16.86Overvalued

Intrinsic value data unavailable for OSRH.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

ONC2 strengths · Avg: 9.5/10
Revenue GrowthGrowth
32.8%10/10

Revenue surging 32.8% year-over-year

Debt/EquityHealth
0.259/10

Conservative balance sheet, low leverage

OSRH1 strengths · Avg: 10.0/10
Price/BookValuation
0.1x10/10

Reasonable price relative to book value

Areas to Watch

ONC4 concerns · Avg: 3.0/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Return on EquityProfitability
7.5%3/10

ROE of 7.5% — below average capital efficiency

Profit MarginProfitability
5.4%3/10

5.4% margin — thin

P/E RatioValuation
111.0x2/10

Premium valuation, high expectations priced in

OSRH4 concerns · Avg: 3.0/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$12.29M3/10

Smaller company, higher risk/reward

Profit MarginProfitability
0.0%3/10

0.0% margin — thin

Return on EquityProfitability
-8.9%2/10

ROE of -8.9% — below average capital efficiency

Comparative Analysis Report

WallStSmart Research

Bull Case : ONC

The strongest argument for ONC centers on Revenue Growth, Debt/Equity. Revenue growth of 32.8% demonstrates continued momentum.

Bull Case : OSRH

The strongest argument for OSRH centers on Price/Book.

Bear Case : ONC

The primary concerns for ONC are EPS Growth, Return on Equity, Profit Margin. A P/E of 111.0x leaves little room for execution misses.

Bear Case : OSRH

The primary concerns for OSRH are EPS Growth, Market Cap, Profit Margin.

Key Dynamics to Monitor

ONC profiles as a hypergrowth stock while OSRH is a value play — different risk/reward profiles.

OSRH carries more volatility with a beta of 1.55 — expect wider price swings.

ONC is growing revenue faster at 32.8% — sustainability is the question.

ONC generates stronger free cash flow (131M), providing more financial flexibility.

Bottom Line

ONC scores higher overall (42/100 vs 23/100) and 32.8% revenue growth. Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

BeiGene, Ltd.

HEALTHCARE · BIOTECHNOLOGY · USA

BeiGene, Ltd., an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. The company is headquartered in Camana Bay, the Cayman Islands.

Visit Website →

OSR Holdings Inc

HEALTHCARE · BIOTECHNOLOGY · USA

OSR Holdings Inc. is a leading provider of integrated managed services specializing in asset management and financial advisory solutions for institutional clients. By harnessing advanced technology and fostering strategic partnerships, the company not only enhances operational efficiency but also broadens its extensive service offerings. OSR Holdings places a strong emphasis on sustainable growth and client-centric value maximization, setting itself apart in a competitive landscape through its dedication to innovation and exceptional customer service. With a keen focus on emerging market opportunities, the firm maintains a rigorous risk management framework to ensure long-term stability and success.

Want to dig deeper into these stocks?